Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy | Citedby Results | Urologia Internationalis | Karger Publishers

Skip to Main Content

Skip Nav Destination

Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

Urol Int (2015) 95 (4): 457–464.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients

Norihisa Katayama
Katsumasa Nakamura
Atsunori Yorozu
Takashi Kikuchi
Masanori Fukushima
Shiro Saito
Takushi Dokiya

Brachytherapy (2019) 18 (5): 574.

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

Wai‐Kit Ma
Darren Ming‐Chun Poon
Chi‐Kwok Chan
Tim‐Wai Chan
Foon‐Yiu Cheung
Lap‐Yin Ho
Eric Ka‐Chai Lee
Angus Kwong‐Chuen Leung
Simon Yiu‐Lam Leung
Hing‐Shing So
Po‐Chor Tam
Philip Wai‐Kay Kwong

BJU International (2019) 124 (2): 221.

High–intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy

Tom Pickles
W. James Morris
Mira Keyes

Brachytherapy (2017) 16 (6): 1101.

American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review

M. Keyes
G. Merrick
S.J. Frank
P. Grimm
M.J. Zelefsky

Brachytherapy (2017) 16 (2): 245.